Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for MAS/sHLH in sJIA or AOSD
NL-OMON50760Phase 2Not yet recruiting
- Sponsor
- Sobi
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of emapalumab, sponsored by Sobi. Planned start May 2018; status: not yet recruiting.
02
Drugs
emapalumab
Beyond the preview
Go deeper on NL-OMON50760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50760.